论文部分内容阅读
目的 :观察蚓激酶对缺血性脑血管病患者血液流变学及纤溶系统的影响及不良反应。方法 :采用多中心、双盲、安慰剂对照的方法治疗缺血性脑血管病恢复期的患者 2 85例。治疗组 2 0 9例予蚓激酶 430mg ,tid ;安慰剂组 76例服安慰剂 2粒 ,tid .疗程均为 4周。结果 :蚓激酶治疗可使血纤维蛋白原降低 (P <0 .0 1) ,部分患者(4 3.1%)D二聚体转为阳性 ,血小板聚集率降低 (P <0 .0 1)。对红细胞计数、血细胞比容、血小板计数也有轻度降低。不良反应发生率为 3.83%。结论 :蚓激酶可作为治疗和预防缺血性脑血管病的安全的药物之一。
Objective: To observe the effect of lumbrokinase on hemorrheology and fibrinolytic system in patients with ischemic cerebrovascular disease and its adverse reactions. Methods: A multicenter, double-blind, placebo-controlled trial of 2 85 patients with ischemic cerebrovascular disease during the recovery phase was performed. Treatment group 209 cases of lumbrokinase 430mg, tid; placebo group 76 placebo 2 tablets, tid. Course of treatment were 4 weeks. RESULTS: Lumbrokinase treatment decreased fibrinogen (P <0.01), and in some patients (41.3%), D dimer turned positive and platelet aggregation rate decreased (P <0.01). On the red blood cell count, hematocrit, platelet count is also slightly reduced. The incidence of adverse reactions was 3.83%. Conclusion: Lumbrokinase can be used as one of the safe drugs for the treatment and prevention of ischemic cerebrovascular diseases.